AR038355A1 - Preparacion liofilizada que comprende inmunocitoquinas - Google Patents

Preparacion liofilizada que comprende inmunocitoquinas

Info

Publication number
AR038355A1
AR038355A1 ARP030100361A ARP030100361A AR038355A1 AR 038355 A1 AR038355 A1 AR 038355A1 AR P030100361 A ARP030100361 A AR P030100361A AR P030100361 A ARP030100361 A AR P030100361A AR 038355 A1 AR038355 A1 AR 038355A1
Authority
AR
Argentina
Prior art keywords
immunocitoquines
liofilized
immunocytokine
preparation including
preparation
Prior art date
Application number
ARP030100361A
Other languages
English (en)
Inventor
Zobel Hans-Peter Dr
Arndt Sven Oliver Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR038355A1 publication Critical patent/AR038355A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Preparación farmacéutica liofilizada que comprende una inmunocitoquina. La preparación tiene una mayor vida en estante, incluso a temperaturas elevadas y, luego de la reconstitución, puede ser administrada como un medicamento por vía parenteral. Reivindicación 1: Preparación farmacéutica liofilizada de inmunocitoquinas, que comprende una inmunocitoquina, un azúcar ó un aminoazúcar, un aminoácido y un agente tensioactivo.
ARP030100361A 2002-02-06 2003-02-05 Preparacion liofilizada que comprende inmunocitoquinas AR038355A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10204792A DE10204792A1 (de) 2002-02-06 2002-02-06 Lyophilisierte Zubereitung enthaltend Immuncytokine

Publications (1)

Publication Number Publication Date
AR038355A1 true AR038355A1 (es) 2005-01-12

Family

ID=27588393

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100361A AR038355A1 (es) 2002-02-06 2003-02-05 Preparacion liofilizada que comprende inmunocitoquinas

Country Status (17)

Country Link
US (1) US20050220758A1 (es)
EP (1) EP1471942A1 (es)
JP (1) JP4422485B2 (es)
KR (1) KR20040091015A (es)
CN (1) CN1627958A (es)
AR (1) AR038355A1 (es)
AU (1) AU2003244470B2 (es)
BR (1) BR0307448A (es)
CA (1) CA2475211A1 (es)
DE (1) DE10204792A1 (es)
MX (1) MXPA04007562A (es)
PE (1) PE20030898A1 (es)
PL (1) PL369754A1 (es)
RU (1) RU2316348C2 (es)
TW (1) TW200303756A (es)
WO (1) WO2003066102A1 (es)
ZA (1) ZA200407028B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
JP2006045162A (ja) * 2004-08-06 2006-02-16 Takeda Chem Ind Ltd 注射用ペプチド含有組成物
JP4948410B2 (ja) * 2004-08-17 2012-06-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−１アンタゴニスト製剤
JPWO2007037330A1 (ja) * 2005-09-28 2009-04-09 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
AR058567A1 (es) * 2005-12-20 2008-02-13 Bristol Myers Squibb Co Formulaciones de proteinas estables
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
ES2525257T3 (es) * 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
CA2920192A1 (en) * 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
CA2947396C (en) 2014-04-28 2021-10-19 Eisai R&D Management Co., Ltd. Lyophilized formulation of hgf
EP3431590B1 (en) 2016-03-17 2021-07-28 Eisai R&D Management Co., Ltd. Method for producing activated hepatocyte growth factor (hgf)
CN114224853B (zh) * 2022-01-04 2022-09-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞刺激因子注射用冻干制剂
CN114515334B (zh) * 2022-02-22 2024-02-20 史辛艺 一种脂肪间充质干细胞因子冻干粉及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
JPS61197527A (ja) * 1985-02-25 1986-09-01 Takeda Chem Ind Ltd インタ−ロイキン−２組成物
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
JP3822383B2 (ja) * 1993-12-17 2006-09-20 持田製薬株式会社 可溶性トロンボモジュリン含有組成物
EP0689843B1 (en) * 1993-12-17 2003-09-10 Mochida Pharmaceutical Co., Ltd. Composition containing soluble thrombomodulins
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern

Also Published As

Publication number Publication date
CA2475211A1 (en) 2003-08-14
MXPA04007562A (es) 2004-11-10
PL369754A1 (en) 2005-05-02
AU2003244470B2 (en) 2008-03-13
BR0307448A (pt) 2004-12-28
WO2003066102A1 (de) 2003-08-14
AU2003244470A1 (en) 2003-09-02
JP4422485B2 (ja) 2010-02-24
KR20040091015A (ko) 2004-10-27
RU2004126942A (ru) 2005-06-10
DE10204792A1 (de) 2003-08-14
RU2316348C2 (ru) 2008-02-10
TW200303756A (en) 2003-09-16
EP1471942A1 (de) 2004-11-03
PE20030898A1 (es) 2003-10-25
JP2005516998A (ja) 2005-06-09
US20050220758A1 (en) 2005-10-06
CN1627958A (zh) 2005-06-15
ZA200407028B (en) 2006-02-22

Similar Documents

Publication Publication Date Title
AR038355A1 (es) Preparacion liofilizada que comprende inmunocitoquinas
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
NO20061055L (no) Administreringsform sikret mot misbruk
PT1180121E (pt) Peptidos insulinotropicos de longa duracao
WO2004000389A3 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
TR200002299T2 (tr) Epotilon kompozisyonları.
BRPI0917535A8 (pt) uso de insulina de ação ultra rápida
ECSP045197A (es) Preparación liofilizada que contiene un anticuerpo contra el receptor EGF
NO20014035L (no) System for oral administrasjon av medikament
AR026764A1 (es) Tratamiento enzimatico para infecciones.
HRP20050371A2 (en) Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
WO2003090696A3 (en) Methods and products for mucosal delivery
WO2009025116A1 (ja) Cdh3ペプチド及びこれを含む薬剤
CR7444A (es) Uso de epotilonas en el tratamiento de enfermedades cerebrales asociadas con procesos proliferativos
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
NZ560648A (en) Formulation for aviptadil (vasoactive intestinal peptide, VIP)
MY129001A (en) Treatment of emphysema using rar selective retinoid antagonists
WO2008030415A3 (en) Medicament reminder device
GEP20063861B (en) Injection solution comprising lhrh antagonist
IT1309453B1 (it) Substrato bioartificiale per la realizzazione di tessuti e organianimali, in particolare umani.
DE60012843D1 (de) Verbindungskontakt und Steckverbinder, welcher diesen Kontakt enthält
NO980887L (no) Formmasser med antikoagulerende egenskaper, deres fremstilling og bearbeiding til gjenstander som finner anvendelser i medisinteknikken
BR9506507A (pt) Forma galênica de derivados de 5-nitro-imadazol composiçoes farmacêuticas microgrânulos gastro-protegidos de derivados de 5-nitro-imidazol e produto da combinaçao
ES2130069B1 (es) Preparacion farmaceutica con liberacion retardada del producto activo.
WO2002047738A3 (de) Biokompatible kolloide mit geringer zelladhäsion und aktiver stabilisierung von blutproteinen

Legal Events

Date Code Title Description
FB Suspension of granting procedure